Vosaroxin

Drug Profile

Vosaroxin

Alternative Names: AG-7352; AG-7352 hydrochloride; QINPREZO; SNS-595; SPC-595; Voreloxin

Latest Information Update: 06 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Dainippon Sumitomo Pharma
  • Developer Sunesis Pharmaceuticals; University of Texas M. D. Anderson Cancer Center; Vanderbilt-Ingram Cancer Center; Washington University School of Medicine; Weill Cornell Medical College
  • Class Antineoplastics; Carboxylic acids; Naphthyridines; Pyrrolidines; Quinolones; Small molecules; Thiazoles
  • Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes
  • Available For Licensing Yes - Acute myeloid leukaemia; Ovarian cancer

Highest Development Phases

  • Phase III Acute myeloid leukaemia
  • Phase I/II Myelodysplastic syndromes
  • Preclinical Glioblastoma
  • Discontinued Non-small cell lung cancer; Ovarian cancer; Small cell lung cancer

Most Recent Events

  • 23 Jun 2017 Efficacy and adverse events data from a phase I/II trial in Myelodysplastic syndrome released by Sunesis Pharmaceuticals
  • 01 May 2017 Regulatory submission withdrawn for Acute myeloid leukaemia (Second-line therapy or greater, In the elderly, Combination therapy) in European Union (IV)
  • 23 Mar 2017 Sunesis submits its responses to the EMA Day 180 List of Outstanding Issues issued by CHMP for MAA approval in Acute myeloid leukaemia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top